Citius Pharmaceuticals is trading at $0.67 (8% up) as it extends its recent rebound, likely driven by broader risk-on sentiment and the ongoing LYMPHIR launch recovery rather than new company-specific news.
- The move aligns with a firmer healthcare sector and follows a period of high volatility for the stock, which can amplify short-term price swings.
- No new company-specific headlines or regulatory filings were identified to explain the August 5 price action.